Can Urol Assoc J. 2025 Sep;19(9):E307-E311. doi: 10.5489/cuaj.9113. ABSTRACT INTRODUCTION: The ability of prostate-specific antigen density (PSAD) to predict metastatic disease on prostate-specific membrane antigen-positron emission tomography (PSMA-PET) at initial staging in high-risk prostate cancer (PCa) for men with negative…
Targeted Radionuclide Therapy Using a Lutetium-177 Labeled Human Anti-CD133 Antibody
Mol Imaging Biol. 2025 Aug;27(4):606-616. doi: 10.1007/s11307-025-02013-4. Epub 2025 May 22. ABSTRACT PURPOSE: Targeted radionuclide therapy against cancer stem cell-specific markers, such as CD133, constitutes a promising strategy to eliminate resilient cancer stem cells for improved outcomes in refractory tumors.…
PSMA PET-detected mesorectal nodal metastasis: treatment outcomes and clinical implications
World J Urol. 2025 Jun 3;43(1):352. doi: 10.1007/s00345-025-05733-y. ABSTRACT PURPOSE: To evaluate the clinical significance of PSMA-PET/CT-detected mesorectal lymph node metastases in biochemically recurrent prostate cancer patients. METHODS: This is a retrospective analysis of biochemically recurrent prostate cancer patients (post-radical…
Convection-enhanced delivery of [177Lu]Lu-labeled gold nanoparticles combined with anti-PD1 checkpoint immunotherapy improves the survival of immunocompetent C57BL/6J mice with orthotopic GL261 murine glioma tumors
Nucl Med Biol. 2025 Jan-Feb;140-141:108970. doi: 10.1016/j.nucmedbio.2024.108970. Epub 2024 Nov 9. ABSTRACT INTRODUCTION: Our objective was to study convection enhanced delivery (CED) of 177Lu-labeled metal chelating polymer (MCP) conjugated to gold nanoparticles (Lu-MCP-AuNP) alone or combined with anti-PD1 immune checkpoint…
18 F-DCFPyL in the Detection of Prostate Cancer Spread to the Lumbosacral Plexus
Clin Nucl Med. 2025 Apr 1;50(4):e232-e233. doi: 10.1097/RLU.0000000000005472. Epub 2024 Dec 13. ABSTRACT In most cases, prostate cancer spreads locally to the seminal vesicles, via lymphatics to pelvic and abdominal lymph nodes, and hematogenously to the bones. Direct invasion along…
Radioimmunotherapy of PANC-1 Human Pancreatic Cancer Xenografts in NRG Mice with Panitumumab Modified with Metal-Chelating Polymers Complexed to 177Lu
Mol Pharm. 2019 Feb 4;16(2):768-778. doi: 10.1021/acs.molpharmaceut.8b01040. Epub 2019 Jan 10. ABSTRACT Our aim was to evaluate the effectiveness and normal tissue toxicity of radioimmunotherapy (RIT) of s.c. PANC-1 human pancreatic cancer (PnCa) xenografts in NRG mice using anti-EGFR panitumumab…
Radioimmunotherapy of human pancreatic cancer xenografts in NOD-scid mice with [64Cu]Cu-NOTA-panitumumab F(ab’)2 alone or combined with radiosensitizing gemcitabine and the PARP inhibitor, rucaparib
Nucl Med Biol. 2020 May-Jun;84-85:46-54. doi: 10.1016/j.nucmedbio.2020.02.001. Epub 2020 Feb 3. ABSTRACT INTRODUCTION: Our objective was to determine the feasibility of extending our previously reported PET imaging study of pancreatic cancer (PnCa) with Cu-NOTA-panitumumab F(ab’)2 to radioimmunotherapy (RIT) by exploiting…
Combination of terbium-161 with somatostatin receptor antagonists-a potential paradigm shift for the treatment of neuroendocrine neoplasms
Eur J Nucl Med Mol Imaging. 2022 Mar;49(4):1113-1126. doi: 10.1007/s00259-021-05564-0. Epub 2021 Oct 8. ABSTRACT PURPOSE: The β¯-emitting terbium-161 also emits conversion and Auger electrons, which are believed to be effective in killing single cancer cells. Terbium-161 was applied with…
Phase I/II Trial of the Combination of 177Lutetium Prostate specific Membrane Antigen 617 and Idronoxil (NOX66) in Men with End-stage Metastatic Castration-resistant Prostate Cancer (LuPIN)
Eur Urol Oncol. 2021 Dec;4(6):963-970. doi: 10.1016/j.euo.2020.07.002. Epub 2020 Aug 3. ABSTRACT BACKGROUND: Trials of lutetium prostate specific membrane antigen (PSMA) in men with metastatic castration-resistant prostate cancer (mCRPC) have demonstrated good safety and efficacy, but combination strategies may improve…
Local Radiation Treatment of HER2-Positive Breast Cancer Using Trastuzumab-Modified Gold Nanoparticles Labeled with 177Lu
Pharm Res. 2017 Mar;34(3):579-590. doi: 10.1007/s11095-016-2082-2. Epub 2016 Dec 16. ABSTRACT PURPOSE: To compare the effectiveness of trastuzumab-modified gold nanoparticles (AuNP) labeled with 177Lu (trastuzumab-AuNP-177Lu) targeted to HER2 with non-targeted AuNP-177Lu for killing HER2-overexpressing breast cancer (BC) cells in vitro…